The physiological processes of the body present daily oscillations called circadian rhythm. The circadian rhythm is essential for maintaining the vital functions of organisms, intervening directly and indirectly in a multitude of key processes, such as hormone secretion, cycles of activity and rest throughout the day, body temperature, the metabolism or absorption, processing and detoxification of nutrients. There are factors such as certain work schedules, prolonged exposure to screens, certain eating patterns or social jetlag, which have a negative impact on the circadian rhythm, causing its disruption and favoring the appearance of health alterations. Thus, there is evidence that associates night shift work with a higher incidence of risk factors for developing metabolic syndrome and cardiovascular diseases, including obesity, elevated blood levels of glucose, triglycerides, and low-density lipoprotein cholesterol (LDL-C), as well as lower levels of high-density lipoprotein cholesterol (HDL-C). In addition, disorders in the sleep cycle are associated with the development of hypertension and type 2 diabetes. Several previous studies show that a grape seed proanthocyanidin extract (GSPE) has beneficial effects on different parameters by restoring the circadian rhythm.
The main objective of the study is to evaluate the effect of daily GSPE intake, in combined with dietary recommendations, on LDL-C levels in individuals with rotating night shift work. The secondary objectives are to evaluate the effects of GSPE on: anthropometric parameters,blood pressure, heart rate and endothelial function, markers of lipid and carbohydrate metabolism and insulin resistance, atherogenic indices, circulating levels of sex hormones and those related to hunger, satiety and stress; markers of systemic inflammation; circadian rhythm markers and sleep quality; level of physical activity, energy consumption, and changes in gene expression of key metabolic enzymes. A randomized, crossover, placebo-controlled, triple-blind nutritional intervention study will be conducted. The study will be carried out in a population of 22 volunteers. Men and women aged 18 years or older, who are working a rotating night shift for at least 1 year and with blood levels of LDL-C between 116 and 190 mg/dL may participate. Each volunteer will make 5 visits to the facilities of the EURECAT Nutrition and Health Technological Unit, in accordance with the study design: * A pre-selection visit (to check inclusion/exclusion criteria), and if the inclusion criteria are met. * Two study visits during consumption of the first product (GSPE or placebo), which will take place on the first day of study (visit 1) and after 6 weeks of treatment (visit 2). * Two study visits during consumption of the second product (GSPE or placebo), which will take place after a three-week washout period (visit 3), and after 6 weeks of treatment (visit 4). The main variable of the CIRCAFENOL study is circulating LDL-C levels.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Enrollment
22
250 mg of product presented in capsule form will be given.
165 mg of cellulose will be given presented in capsule form.
Eurecat
Reus, Tarragona, Spain
NOT_YET_RECRUITINGFundació EURECAT
Reus, Tarragona, Spain
RECRUITINGChange in LDL cholesterol levels.
Serum LDL cholesterol levels will be measured by commercial colorimetric kit.
Time frame: Before (baseline) and after treatment period (6 weeks) for each of the two treatments (GSPE and placebo).
Change in body weight.
Body weight will be measured by standardized method.
Time frame: Before (baseline) and after treatment period (6 weeks) for each of the two treatments (GSPE and placebo).
Height.
Height will be measured by standardized method.
Time frame: At week 1.
Change in BMI.
Weight and height will be combined to report BMI in kg/m\^2.
Time frame: Before (baseline) and after treatment period (6 weeks) for each of the two treatments (GSPE and placebo).
Change in waist circumference.
Waist circumference will be measured using a measuring tape.
Time frame: Before (baseline) and after treatment period (6 weeks) for each of the two treatments (GSPE and placebo).
Change in conicity index.
Weight, height and waist circumference will be combined to report Conicity index.
Time frame: Before (baseline) and after treatment period (6 weeks) for each of the two treatments (GSPE and placebo).
Change in waist circumference to height ratio.
Waist circumference and height will be combined to report Waist circumference to Height ratio.
Time frame: Before (baseline) and after treatment period (6 weeks) for each of the two treatments (GSPE and placebo).
Change in the amount of body fat.
Body fat will be measured by TANITA SC330.
Time frame: Before (baseline) and after treatment period (6 weeks) for each of the two treatments (GSPE and placebo).
Change in the amount of muscle mass.
Muscle mass will be measured by TANITA SC330.
Time frame: Before (baseline) and after treatment period (6 weeks) for each of the two treatments (GSPE and placebo).
Change in the amount of bone mass.
Bone mass will be measured by TANITA SC330.
Time frame: Before (baseline) and after treatment period (6 weeks) for each of the two treatments (GSPE and placebo).
Change in the amount of total body water.
Total body water will be measured by TANITA SC330.
Time frame: Before (baseline) and after treatment period (6 weeks) for each of the two treatments (GSPE and placebo).
Change in systolic blood pressure.
Systolic blood pressure will be measured using an automatic sphygmomanometer.
Time frame: Before (baseline) and after treatment period (6 weeks) for each of the two treatments (GSPE and placebo).
Change in diastolic blood pressure.
Diastolic blood pressure will be measured using an automatic sphygmomanometer.
Time frame: Before (baseline) and after treatment period (6 weeks) for each of the two treatments (GSPE and placebo).
Change in resting heart rate.
Resting heart rate will be measured using an automatic sphygmomanometer.
Time frame: Before (baseline) and after treatment period (6 weeks) for each of the two treatments (GSPE and placebo).
Change in endothelial function.
Endothelial function will be measured using the Laser-Doppler technique.
Time frame: Before (baseline) and after treatment period (6 weeks) for each of the two treatments (GSPE and placebo).
Change in serum total cholesterol levels.
Serum total cholesterol levels will be measured by standardized ultraviolet-visible spectrophotometry methods.
Time frame: Before (baseline) and after treatment period (6 weeks) for each of the two treatments (GSPE and placebo).
Change in serum HDL-c levels.
Serum HDL-c levels will be measured by standardized ultraviolet-visible spectrophotometry methods.
Time frame: Before (baseline) and after treatment period (6 weeks) for each of the two treatments (GSPE and placebo).
Change in serum Triglycerides levels.
Serum triglycerides levels will be measured by standardized ultraviolet-visible spectrophotometry methods.
Time frame: Before (baseline) and after treatment period (6 weeks) for each of the two treatments (GSPE and placebo).
Change in total cholesterol to HDL-c ratio.
Total cholesterol and HDL-c values will be combined to report Total cholesterol to HDL-c ratio.
Time frame: Before (baseline) and after treatment period (6 weeks) for each of the two treatments (GSPE and placebo).
Change in LDL-c to HDL-c ratio.
LDL-c and HDL-c values will be combined to report LDL-c to HDL-c ratio.
Time frame: Before (baseline) and after treatment period (6 weeks) for each of the two treatments (GSPE and placebo).
Change in Plasma atherogenic index.
Plasma atherogenic index will be calculated as the logarithm of the triglycerides levels to HDL-c levels ratio.
Time frame: Before (baseline) and after treatment period (6 weeks) for each of the two treatments (GSPE and placebo).
Change in serum glucose levels.
Serum glucose levels will be measured by standardized ultraviolet-visible spectrophotometry methods.
Time frame: Before (baseline) and after treatment period (6 weeks) for each of the two treatments (GSPE and placebo).
Change in serum insulin levels.
Serum insulin levels will be measured by spectrophotometry methods.
Time frame: Before (baseline) and after treatment period (6 weeks) for each of the two treatments (GSPE and placebo).
Change in serum glycosylated hemoglobin levels.
Serum glycosylated hemoglobin levels will be measured by commercial kits.
Time frame: Before (baseline) and after treatment period (6 weeks) for each of the two treatments (GSPE and placebo).
Change in Homeostatic Model Assessment from Insulin Resistance Index (HOMA-IR).
HOMA-IR will be calculated using serum glucose and insulin levels.
Time frame: Before (baseline) and after treatment period (6 weeks) for each of the two treatments (GSPE and placebo).
Change in serum high sensitivity c-reactive protein levels.
Serum C-Reactive protein levels will be measured by plate test and by the agglutination of latex particles.
Time frame: Before (baseline) and after treatment period (6 weeks) for each of the two treatments (GSPE and placebo).
Change in serum ghrelin levels.
Serum ghrelin levels will be measured by ELISA kits.
Time frame: Before (baseline) and after treatment period (6 weeks) for each of the two treatments (GSPE and placebo).
Change in serum leptin levels.
Serum leptin levels will be measured by ELISA kits.
Time frame: Before (baseline) and after treatment period (6 weeks) for each of the two treatments (GSPE and placebo).
Change in circulating thyroid hormone T3 levels.
Serum T3 levels will be measured by liquid chromatography coupled to mass spectrometry with triple quadrupole detector (LC-TQD-MS/MS).
Time frame: Before (baseline) and after treatment period (6 weeks) for each of the two treatments (GSPE and placebo).
Change in circulating thyroid hormone T4 levels.
SerumT4 levels will be measured by liquid chromatography coupled to mass spectrometry with triple quadrupole detector (LC-TQD-MS/MS).
Time frame: Before (baseline) and after treatment period (6 weeks) for each of the two treatments (GSPE and placebo).
Change in circulating testosterone levels.
Serum testosterone levels will be measured by liquid chromatography coupled to mass spectrometry with triple quadrupole detector (LC-TQD-MS/MS).
Time frame: Before (baseline) and after treatment period (6 weeks) for each of the two treatments (GSPE and placebo).
Change in circulating estrone levels.
Serum estrone levels will be measured by liquid chromatography coupled to mass spectrometry with triple quadrupole detector (LC-TQD-MS/MS).
Time frame: Before (baseline) and after treatment period (6 weeks) for each of the two treatments (GSPE and placebo).
Change in circulating 17-β-Estradiol levels.
Serum 17-β-Estradiol levels will be measured by liquid chromatography coupled to mass spectrometry with triple quadrupole detector (LC-TQD-MS/MS).
Time frame: Before (baseline) and after treatment period (6 weeks) for each of the two treatments (GSPE and placebo).
Change in circulating estriol levels.
Serum estriol levels will be measured by liquid chromatography coupled to mass spectrometry with triple quadrupole detector (LC-TQD-MS/MS).
Time frame: Before (baseline) and after treatment period (6 weeks) for each of the two treatments (GSPE and placebo).
Change in serum melatonin levels.
Serum melatonin levels will be measured by liquid chromatography coupled to mass spectrometry with triple quadrupole detector (LC-TQD-MS/MS).
Time frame: Before (baseline) and after treatment period (6 weeks) for each of the two treatments (GSPE and placebo).
Change in urine 6-Sulfatoxymelatonin levels.
6-Sulfatoxymelatonin levels will be measured in spontaneous urine samples from two times of the day: morning and night by ELISA kit.
Time frame: Before (baseline) and after treatment period (6 weeks) for each of the two treatments (GSPE and placebo).
Change in activity and rest cycles (subjective measurement).
Activity and rest cycles will be measured subjectively by dream diaries. The sleep diary will be self-completed by the participant and will determine the time at which the person attempted to sleep, the duration and interruptions of nighttime sleep, the person's sleep pattern, and how much of the day the person was active.
Time frame: Before (baseline) and after treatment period (6 weeks) for each of the two treatments (GSPE and placebo).
Change in activity and rest cycles (objective measurement).
Activity and rest cycles will be measured objectively by actigraphs. The wrist actigraphs will be worn 24 hours a day and will measure heart rate, which will give an idea of the amount of time the person was asleep and active.
Time frame: Before (baseline) and after treatment period (6 weeks) for each of the two treatments (GSPE and placebo).
Pittsburgh Sleep Quality Index.
It is a validated scale that measures the usual sleep habits during the past month. It consist of 7 areas: subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of sleep medication, and daytime dysfunction. It contains a total of 19 items, grouped into 10 questions where each of the areas evaluated is a scored between 0 and 3. The scores from the seven areas are finally added up to give an overall score. The component score are summed to produce a global score (range 0 to 21). Higher score indicate worse sleep quality.
Time frame: Before (baseline) and after treatment period (6 weeks) for each of the two treatments (GSPE and placebo).
Chronotype.
The chronotype will be evaluated using the Horne-Ostberg Morningness-Eveningness Questionnaire. Which consists of 19 questions that will allow volunteers to be classified into morning, night or intermediate people.
Time frame: Before (baseline) and after treatment period (6 weeks) for each of the two treatments (GSPE and placebo).
Change in circulating GSPE metabolites.
GSPE metabolites will be measured by LC-TQD-MS/MS.
Time frame: Before (baseline) and after treatment period (6 weeks) for each of the two treatments (GSPE and placebo).
Change in food consumption habits.
Food consumption will be evaluated through a 3-day food record.
Time frame: Before (baseline) and after treatment period (6 weeks) for each of the two treatments (GSPE and placebo).
Change in Physical activity.
Physical activity will be evaluated through the Physical Activity Questionnaire, Quick Physical Activity Classifier, adapted from the PEFS guide of the Generalitat de Catalunya. The questionnaire asks about three specific types of activity (walking, moderate-intensity activities and vigorous intensity activities) in the set domains leisure time, domestic and gardening (yard) activities, work-related and transport-related activities. Frequency and duration are collected separately for each specific type of activity.
Time frame: Before (baseline) and after treatment period (6 weeks) for each of the two treatments (GSPE and placebo).
Change in body temperature.
Body temperature will be measured using a infrared thermometer according to a standardized measurement protocol.
Time frame: Before (baseline) and after treatment period (6 weeks) for each of the two treatments (GSPE and placebo).
Change in gene expression in peripheral blood mononuclear cells.
The expression of key genes in lipid and carbohydrate metabolism and regulation of the circadian rhythm will be measured through transcriptomic analysis, performing RNA extraction, conversion to cDNA and subsequent analysis.
Time frame: Before (baseline) and after treatment period (6 weeks) for each of the two treatments (GSPE and placebo).
Change in serum metabolite profile.
serum metabolites will be determined by LC-TQD-MS/MS.
Time frame: Before (baseline) and after treatment period (6 weeks) for each of the two treatments (GSPE and placebo).
Adverse events
Possible adverse events derived from taking study's products will be recorded.
Time frame: Before (baseline) and after treatment period (6 weeks) for each of the two treatments (GSPE and placebo).
Consumption of dietary supplements.
Dietary supplements consumed during the study will be recorded in the case report form.
Time frame: Before (baseline) and after treatment period (6 weeks) for each of the two treatments (GSPE and placebo).
Concomitant medication.
Concomitant medication will be recorded in the case report form.
Time frame: Before (baseline) and after treatment period (6 weeks) for each of the two treatments (GSPE and placebo).
Age.
Age will be recorded in years. It will be recorded in the case report form.
Time frame: At week 1.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.